Cancer therapies targeting exosomal RNA: strategies for blocking cell-to-cell signals and delivering nucleic acids
RNA regulation beyond cancer cells
RNA carried by exosomes alters gene expression in nearby cells and contributes to cancer progression and treatment resistance. A review by Sharma and colleagues in Discover Oncology summarizes strategies to block this intercellular communication and approaches that use exosomes as carriers for therapeutic nucleic acids. It brings together existing mechanistic studies, preclinical examples, and clinical development challenges; it is not a study validating the efficacy of a new integrated therapeutic approach.
Exosomes are small membrane-bound vesicles secreted by various cell types. The review describes them as 30–150 nm in size and explains that they carry microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and messenger RNAs (mRNAs), among other cargo. These RNAs can regulate mRNA stability and protein synthesis in recipient cells. The review begins by examining regulatory relationships that extend beyond gene expression within cancer cells to nearby immune and stromal cells.
Targets for blocking signals and carriers for RNA delivery
One mechanism discussed in the review involves exosomal miR-21 lowering the expression of PTEN and PDCD4, which are involved in tumor suppression, in recipient cells. It is described as strengthening tumor-promoting signals by repressing target mRNA translation or promoting mRNA degradation. Delivery of regulatory RNA should be distinguished from genome editing that permanently changes DNA sequences.
The therapeutic strategies fall into two broad categories. The first aims to reduce delivery of tumor-promoting cargo by inhibiting exosome production, release, or uptake. For inhibiting production and release, the review discusses GW4869, a neutral sphingomyelinase inhibitor, and inhibition of Rab proteins involved in vesicle trafficking. However, cases of Rab27A-dependent vesicle release that is not inhibited by GW4869 indicate that blocking every communication pathway with a single inhibitor is difficult. Blocking exosome uptake by recipient cells is considered separately from inhibiting production and release.
The second strategy uses exosomes to deliver therapeutic nucleic acids. According to the review, exosomes carrying small interfering RNA (siRNA) targeting the KRAS G12D mutation inhibited tumor growth in a mouse model of pancreatic cancer. A separate pancreatic cancer study reported that changing the exosomal miRNA composition shifted macrophages from a tumor-promoting M2 state to an antitumor M1 state. These findings came from different models and should not be combined into a claim that one treatment controlled the immune and stromal environment as well as metastasis.
The review also covers CRISPR/Cas13, an RNA-targeting technology. Cas13 cleaves target RNA; linking catalytically inactive Cas13 to an RNA-editing enzyme enables its use for RNA base editing. Its mechanism differs from that of Cas9, which targets DNA. The Cas9 delivery experiments discussed in the review do not demonstrate clinical efficacy for exosome-based Cas13 therapy.
Selectivity and manufacturing quality shape clinical application
Current evidence comes primarily from cell and animal models. The review also describes early clinical development, but notes that evidence establishing therapeutic benefit in patients and long-term safety remains limited. Its assessment is that although individual strategies can inhibit specific exosome functions, they have not yet achieved comprehensive and selective blockade of pathological exosome activity.
The advantages of exosomes as carriers are also conditional. Their membranes can protect RNA, but natural exosomes do not selectively target tumor cells alone, so uptake by normal cells and toxicity must also be assessed. Nucleic acid loading efficiency, distribution in the body, large-scale production and purification, and batch-to-batch quality consistency remain development challenges. Differences in isolation and measurement methods further complicate direct comparisons across studies. Future development should assess not only tumor suppression, but also the amount delivered to target cells and the effects on normal tissues.
Sources: Full text of the Discover Oncology review, DOI: 10.1007/s12672-026-05255-y.
Oncology & Molecular Vesicle Core, Published May 2026. DOI: [Source Generated Data]
Summary: Resolving the challenges of horizontal oncogenic signaling within the tumor microenvironment (TME), this study elucidates the post-transcriptional regulatory networks directed by tumor-derived exosomes. Characterized as 30-150 nm vesicles, these entities translocate bioactive cargos—including miRNAs, lncRNAs, circRNAs, and mRNAs—to enforce translation repression, alternative splicing interference, and epigenetic remodeling across target stroma. To disrupt this intercellular pathomechanism, the framework deploys a multi-tiered architecture: blocking exosome biogenesis and release via GW4869 and Rab GTPase inhibitors, alongside high-fidelity cargo neutralization utilizing antisense oligonucleotides, RNAi, and CRISPR/Cas13 RNA editing. Concurrently, utilizing these vesicles as biocompatible, low-immunogenicity therapeutic carriers for programmable nucleotide delivery successfully reverses M2 macrophage polarization and cancer-associated fibroblast transformation, delivering a robust, low-noise computational baseline for targeted precision oncology.
Exosome research points to two development paths: targets for blocking RNA communication from cancer cells and carriers for therapeutic RNA. For example, developers of a carrier for KRAS G12D-targeting siRNA could use the tumor-suppression result in the mouse model described in the review as a starting point for further validation. However, evidence is insufficient to extrapolate that result to therapeutic benefit in humans. Development studies need to assess RNA delivery and gene suppression within target cells alongside normal-cell exposure and safety with repeated dosing. Reproducibility of loading amount, purity, and biological activity across production batches is another criterion. This review offers a framework for evaluating efficacy evidence alongside delivery and manufacturing risks for each candidate strategy.